NCT03867383View on ClinicalTrials.gov

Calcium Chloride for Prevention of Uterine Atony During Cesarean

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

July 30, 2021

Study Completion Date

August 15, 2021

Conditions
Uterine AtonyUterine Atony With HemorrhageCesarean Section Complications
Interventions
DRUG

Calcium Chloride

"All included in intervention description.~1 gram of calcium chloride in total 60 milliliters normal saline"

DRUG

Placebo

60 milliliters normal saline

Trial Locations (1)

94305

Lucile Packard Children's Hospital, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT03867383 - Calcium Chloride for Prevention of Uterine Atony During Cesarean | Biotech Hunter | Biotech Hunter